Medical technology company Intuitive Surgical (NASDAQ:ISRG) will be reporting results tomorrow after market close. Here’s what investors should know.

Intuitive Surgical beat analysts’ revenue expectations by 6.5% last quarter, reporting revenues of $2.41 billion, up 25.2% year on year. It was an incredible quarter for the company, with an impressive beat of analysts’ sales volume and EPS estimates.

Is Intuitive Surgical a buy or sell going into earnings? Read our full analysis here, it’s free.

This quarter, analysts are expecting Intuitive Surgical’s revenue to grow 15.6% year on year to $2.19 billion, improving from the 11.5% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.73 per share.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Intuitive Surgical has only missed Wall Street’s revenue estimates once over the last two years, exceeding top-line expectations by 1.2% on average.

Looking at Intuitive Surgical’s peers in the healthcare equipment and supplies segment, some have already reported their Q1 results, giving us a hint as to what we can expect. Abbott Laboratories delivered year-on-year revenue growth of 4%, meeting analysts’ expectations, and Neogen reported a revenue decline of 3.4%, falling short of estimates by 1.5%. Abbott Laboratories traded up 3.8% following the results while Neogen was down 20%.

Read our full analysis of Abbott Laboratories’s results here and Neogen’s results here.

Unless you’ve been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. We prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story.